Benefits
Acute diarrhea treatment 1,143-patient RCT
Treatment RCT in 1,143 patients with acute infectious diarrhea: SF68 three times daily for 7 days reduced median time to resolution of diarrhea from 4 days to 3 days. Time to resolution of secondary symptoms also significantly reduced. Large RCT sample size with statistically robust effect.
AAD prevention 1,397-patient RCT
AAD prevention RCT in 1,397 patients on antibiotics: SF68 twice daily for 7 days reduced AAD incidence from 16.2% (placebo) to 8.6%, approximately a 47% absolute risk reduction. Among the strongest AAD prevention effect sizes in the probiotic literature.
Cochrane Review confirmation (4 RCTs, n=333)
A Cochrane Review on probiotic treatment of acute infectious diarrhea included 4 SF68 RCTs (n=333) demonstrating reduced risk for diarrhea >=4 days. Honest limitation acknowledged in the Cochrane review itself: trial quality assessed as insufficient, with unclear or inadequate allocation concealment, no blinding in some trials, and no/unclear intention-to-treat analyses.
Licensed pharmaceutical status (Austria, Italy, Switzerland)
Approved as a pharmaceutical drug for acute infectious enteritis treatment, traveler's diarrhea, and AAD in three European countries. Joins Bacillus clausii (Enterogermina), E. coli Nissle 1917 (Mutaflor), and Clostridium butyricum MIYAIRI 588 (MIYA-BM) in the rare category of probiotics with pharmaceutical licensure rather than dietary-supplement-only status.
Arginine deiminase mechanism evidence
SF68 arginine deiminase inhibits host cell NF-κB and JNK(AP-1) pathway activation, supporting anti-inflammatory and immunomodulatory effects. A distinguishing biochemical mechanism specific to this strain.
Favorable adverse event profile
AE incidence 1.1-1.4% in RCTs, 4.7-7.4% in open-label studies. Discontinuation due to intolerability was actually more frequent in placebo (0.7% vs 0.1%, not statistically significant) — suggesting the probiotic was at least as well-tolerated as placebo.
Honest safety considerations (Enterococcus species)
Enterococcus species generally raise vancomycin-resistance concerns. SF68's specific human safety record (including pharmaceutical licensing in 3 countries) mitigates but does not fully eliminate species-level concerns. Some animal infection studies report no benefit or adverse effects (higher bacterial loads, Salmonella Typhimurium shedding) in models that don't translate cleanly to human use — limiting interpretation for veterinary applications more than human.
Mechanism of action
Arginine deiminase NF-κB and JNK(AP-1) inhibition
SF68 arginine deiminase enzyme inhibits host cell NF-κB and JNK(AP-1) pathway activation, the proposed biochemical basis for the anti-inflammatory and immunomodulatory effects underlying clinical efficacy.
Time-to-resolution acceleration
An ~1-day median reduction in time to diarrhea resolution has been demonstrated. The mechanism is likely multifactorial: inflammation reduction, competitive exclusion of pathogens, and barrier support.
AAD prevention via competitive exclusion
47% absolute risk reduction in AAD development. The mechanism likely involves niche occupation during antibiotic-induced dysbiosis, preventing C. difficile and other opportunistic species from establishing.
Acid and bile resistance
SF68 shows efficient delivery without specialized formulation — no enteric coating required. Practical formulation advantage for shelf-stable products.
Intestinal inflammation mitigation
The arginine deiminase pathway inhibits NF-κB and AP-1 activation, reducing intestinal inflammation. Mechanistic basis for the diarrhea-shortening effect — inflammation is a core driver of secretory and inflammatory diarrhea.
Enterococcus species safety considerations
Enterococci can carry vancomycin resistance genes. SF68's specific human-safety record across pharmaceutical use mitigates this concern, but the species-level consideration remains relevant for immunocompromised populations and for any new strains/products beyond licensed Bioflorin.
Clinical trials
Clinical evidence on Enterococcus faecium SF68® (Bioflorin / Cernivet) for the indications and outcomes described.
Clinical population described in trial publication.
Greuter T et al. 2020 (Front Med 7:276, doi:10.3389/fmed.2020.00276). Analysis of 4 SF68 studies. Treatment clinical trial (n=1,143): TID for 7 days reduced median time to diarrhea resolution 3 vs 4 days (P<0.001). AAD prevention clinical trial (n=1,397): BID for 7 days reduced AAD development 8.6% vs 16.2% (P<0.001, ~47% absolute risk reduction). Open-label study (n=4,340) consistent with clinical trial findings. Honest limitation: analysis based on previously unpublished studies.
Cochrane Review included 4 SF68 clinical trials (n=333) demonstrating reduced risk for diarrhea ≥4 days.
Clinical population described in trial publication.
Cochrane Review included 4 SF68 clinical trials (n=333) demonstrating reduced risk for diarrhea ≥4 days. Honest limitation: trial quality assessed as insufficient with unclear/inadequate allocation concealment, no blinding in some, and no/unclear ITT analyses. Methodological caveats are part of the honest evidence picture for this strain.
Gut (doi:10.1080/19490976.2022.2106105) — SF68 arginine deiminase inhibits host cell NF-κB and JNK(AP-1) pathway activation.
Clinical population described in trial publication.
Gut (doi:10.1080/19490976.2022.2106105) — SF68 arginine deiminase inhibits host cell NF-κB and JNK(AP-1) pathway activation. Distinguishing biochemical mechanism specific to this strain, supporting the anti-inflammatory and immunomodulatory effects.